Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Citation Manager Formats
Make Comment
See Comments
See original article:

In the Clinical/Scientific Note "Dramatic rebounds of MS during pregnancy following fingolimod withdrawal” by G. Novi et al.,1 there is an error in the study funding statement, which should have specified, “Some of the results discussed in this publication were supported by Compagnia di San Paolo.” The authors regret the omission.
- © 2018 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
-
Article
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosisGoeril Karlsson, Gordon Francis, Gideon Koren et al.Neurology, January 24, 2014 -
Clinical and Ethical Challenges
Postmarketing adverse drug reactionsA duty to report?Eran Klein, Dennis Bourdette et al.Neurology: Clinical Practice, July 19, 2013 -
Special Article
Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyMauricio F. Farez, Jorge Correale, Melissa J. Armstrong et al.Neurology, August 28, 2019 -
Articles
Disease-modifying drugs for multiple sclerosis in pregnancyA systematic reviewEllen Lu, Bing Wei Wang, Colleen Guimond et al.Neurology, August 29, 2012